LIU Jinsong--Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences

Study/Work Experience

2005.11 – now	Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences/ Principle Investigator
2004.08 – 2005.10	Amgen Inc./Senior Scientist
2000.02 – 2004.08	Tularik Inc./Scientist
2000.01 – 2000.02	Rutgers University/Postdoc
1994.01 – 2000.01	Rutgers University/Ph. D
1988.09 – 1992.07	Peking University/B. S

Research Areas

Dr. Jinsong Liu is a structural biologist who has worked for over five years with biotechnology companies from the USA before coming back to China at the end of 2005. He is an author of over 70 peer-reviewed journal articles and patents. Before joining Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), he was a Senior Scientist at Amgen Inc. Prior to that, he was a Scientist at Tularik Inc., a biotechnology company located at South San Francisco. While working at Tularik/Amgen, he participated in numerous projects using structural biology as a tool for drug discovery. Drug targets he has worked on include protein kinases, nuclear hormone receptors and various enzymes. Since he joined GIBH at the end of 2005, he has setup a structural biology laboratory and determined several disease related protein structures.

Academic Performance

Dr. Jinsong Liu is a structural biologist who has worked for over five years with biotechnology companies from the USA before coming back to China at the end of 2005. He is an author of over 70 peer-reviewed journal articles and patents. Before joining Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), he was a Senior Scientist at Amgen Inc. Prior to that, he was a Scientist at Tularik Inc., a biotechnology company located at South San Francisco. While working at Tularik/Amgen, he participated in numerous projects using structural biology as a tool for drug discovery. Drug targets he has worked on include protein kinases, nuclear hormone receptors and various enzymes. Since he joined GIBH at the end of 2005, he has setup a structural biology laboratory and determined several disease related protein structures.

Representative Papers

1. Hou S, Xu T,……, Chen L, Liu J*. Structural basis for functional selectivity and ligand recognition revealed by crystal structures of human secreted phospholipase A2 group IIE. Scientific reports. 2017 Sep ;7(1):10815

2. Xu J, Zhang L,……, Shu X*,Liu J*. SNX16 Regulates the Recycling of E-Cadherin through a Unique Mechanism of Coordinated Membrane and Cargo Binding. Structure. 2017 Aug ;25(8):1251-1263

3. Xu J, Xu T,……, Pei D, Liu J*. Structure of sorting nexin 11 (SNX11) reveals a novel extended phox homology (PX) domain critical for inhibition of SNX10-induced vacuolation. The Journal of biological chemistry. 2013 Jun;288(23):16598-16605

4. Wang Z, Benoit G, Liu J,……, Liu X, Xu H, Walker NP*, Perlmann T*. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature. 2003 May;423(6939):555-560

5. Liu J, Lynch PA, Chien CY, Montelione GT, Krug RM, Berman HM*. Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat Struct Biol. 1997 Nov;4(11):896-899